Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma
July 6th 2022Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.
Read More
Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape
June 15th 2022The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.
Read More
Venetoclax Plus Obinutuzumab Confers Long-Term Survival Benefits in Unfit Patients With CLL
June 13th 2022Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.
Read More
BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL
June 12th 2022The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.
Read More
Epcoritamab Plus GemOX Exhibits Promising Early Efficacy in R/R DLCBL
June 10th 2022Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.
Read More
BRUIN CLL-321 Aims to Expand BTK Inhibitor Options in CLL/SLL
June 8th 2022The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.
Read More
Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma
June 5th 2022Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.
Read More
Palbociclib Plus Letrozole Misses OS End Point in ER+/HER2- Advanced Breast Cancer
June 4th 2022First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.
Read More
Galinpepimut-S Plus Pembrolizumab Displays Early Efficacy in WT1+ Ovarian Cancer
May 31st 2022Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).
Read More
Pembrolizumab Monotherapy Adds Option in MSI-H/dMMR Endometrial Cancer
May 18th 2022The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
Read More
IS-002 Improves Prostate Cancer Visualization Prior to Robotic Prostatectomy
May 16th 2022The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.
Read More
Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma
May 14th 2022According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.
Read More
Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer
May 12th 2022Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.
Read More
Pembrolizumab Plus Chemotherapy Does Not Significantly Affect QOL in PD-L1+ TNBC
May 6th 2022The addition of pembrolizumab to chemotherapy led to significant survival benefits without substantial deterioration in health-related quality of life among patients with treatment-naïve, PD-L1–positive advanced triple-negative breast cancer according to results from the phase 3 KEYNOTE-355 trial.
Read More
Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer
May 6th 2022Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.
Read More
TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies
April 25th 2022Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.
Read More
Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma
April 21st 2022The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.
Read More